LANTHANUM CARBONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lanthanum Carbonate, and when can generic versions of Lanthanum Carbonate launch?
Lanthanum Carbonate is a drug marketed by Barr, Invagen Pharms, and Natco Pharma Ltd. and is included in three NDAs.
The generic ingredient in LANTHANUM CARBONATE is lanthanum carbonate. There are nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lanthanum carbonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lanthanum Carbonate
A generic version of LANTHANUM CARBONATE was approved as lanthanum carbonate by NATCO PHARMA LTD on August 11th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LANTHANUM CARBONATE?
- What are the global sales for LANTHANUM CARBONATE?
- What is Average Wholesale Price for LANTHANUM CARBONATE?
Summary for LANTHANUM CARBONATE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 36 |
| Clinical Trials: | 43 |
| Patent Applications: | 594 |
| Drug Prices: | Drug price information for LANTHANUM CARBONATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LANTHANUM CARBONATE |
| What excipients (inactive ingredients) are in LANTHANUM CARBONATE? | LANTHANUM CARBONATE excipients list |
| DailyMed Link: | LANTHANUM CARBONATE at DailyMed |
Recent Clinical Trials for LANTHANUM CARBONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Medical Universtity of Lodz | Phase 4 |
| Medical University of Lodz | Phase 4 |
| Universitair Ziekenhuis Brussel | Phase 3 |
Pharmacology for LANTHANUM CARBONATE
| Drug Class | Phosphate Binder |
| Mechanism of Action | Phosphate Chelating Activity |
Anatomical Therapeutic Chemical (ATC) Classes for LANTHANUM CARBONATE
Paragraph IV (Patent) Challenges for LANTHANUM CARBONATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| FOSRENOL | Oral Powder | lanthanum carbonate | 750 mg and 1000 mg | 204734 | 1 | 2015-11-25 |
| FOSRENOL | Chewable Tablet | lanthanum carbonate | 500 mg, 750 mg and 1000 mg | 021468 | 3 | 2008-10-27 |
US Patents and Regulatory Information for LANTHANUM CARBONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Barr | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090977-003 | Jan 27, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Natco Pharma Ltd | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090978-003 | Aug 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 206868-003 | Jan 24, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Natco Pharma Ltd | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090978-001 | Aug 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Barr | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090977-001 | Jan 27, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Barr | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 090977-002 | Jan 27, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Invagen Pharms | LANTHANUM CARBONATE | lanthanum carbonate | TABLET, CHEWABLE;ORAL | 206868-002 | Jan 24, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
